{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T05:01:16Z","timestamp":1794805276047,"version":"4.9.1"},"reference-count":138,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jceh.2021.08.017","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T11:35:38Z","timestamp":1629718538000},"page":"155-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["A Current Understanding of Bile Acids in Chronic Liver Disease"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2429-4627","authenticated-orcid":false,"given":"Naba","family":"Farooqui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshuman","family":"Elhence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1247-437X","authenticated-orcid":false,"family":"Shalimar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2021.08.017_bib1","unstructured":"The Top 10 Causes of Death. Accessed May 28, 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death."},{"key":"10.1016\/j.jceh.2021.08.017_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41575-018-0055-0","article-title":"The changing epidemiology of liver diseases in the Asia-Pacific region","volume":"16","author":"Wong","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib3","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2021.08.017_bib4","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jhep.2018.05.011","article-title":"Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies","volume":"69","author":"Pimpin","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib5","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","article-title":"Altered profile of human gut microbiome is associated with cirrhosis and its complications","volume":"60","author":"Bajaj","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0022-2275(20)30185-1","article-title":"Removal of the bile acid pool upregulates cholesterol 7alpha-hydroxylase by deactivating FXR in rabbits","volume":"43","author":"Xu","year":"2002","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jceh.2021.08.017_bib7","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jceh.2021.08.017_bib8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metabol"},{"key":"10.1016\/j.jceh.2021.08.017_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/cld.861","article-title":"Bile acid biology, pathophysiology, and therapeutics","volume":"15","author":"Chiang","year":"2020","journal-title":"Clinical Liver Disease"},{"key":"10.1016\/j.jceh.2021.08.017_bib10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0016-5085(71)80053-7","article-title":"Bile acid metabolism in patients with cirrhosis","volume":"60","author":"Vlahcevic","year":"1971","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2021.08.017_bib11","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MOG.0000000000000057","article-title":"Bile acids and the gut microbiome","volume":"30","author":"Ridlon","year":"2014","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.jceh.2021.08.017_bib12","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2013.01.003","article-title":"Modulation of the fecal bile acid profile by gut microbiota in cirrhosis","volume":"58","author":"Kakiyama","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib13","first-page":"305","article-title":"Absence of intestinal bile promotes bacterial translocation","volume":"58","author":"Slocum","year":"1992","journal-title":"Am Surg"},{"key":"10.1016\/j.jceh.2021.08.017_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000129252","article-title":"The role of bile and bile acids in bacterial translocation in obstructive jaundice in rats","volume":"25","author":"Ding","year":"1993","journal-title":"Eur Surg Res"},{"key":"10.1016\/j.jceh.2021.08.017_bib15","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jhep.2012.01.019","article-title":"Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease","volume":"56","author":"Fouts","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib16","first-page":"425","article-title":"Therapeutic roles of bile acid signaling in chronic liver diseases","volume":"6","author":"Li","year":"2018","journal-title":"J\u00a0Clin Transl Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib17","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.08.017_bib18","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4161\/gmic.25723","article-title":"Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship","volume":"4","author":"Ridlon","year":"2013","journal-title":"Gut Microb"},{"key":"10.1016\/j.jceh.2021.08.017_bib19","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/gutjnl-2016-313332","article-title":"Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy","volume":"67","author":"Tang","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2021.08.017_bib20","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/liv.14153","article-title":"The gut microbial influence on cholestatic liver disease","volume":"39","author":"Kummen","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2021.08.017_bib21","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.3748\/wjg.v23.i25.4548","article-title":"Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis","volume":"23","author":"Bajer","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2021.08.017_bib22","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.3748\/wjg.v26.i21.2768","article-title":"Gut microbiome in primary sclerosing cholangitis: a review","volume":"26","author":"Little","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2021.08.017_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17111864","article-title":"Impact of microbes on the pathogenesis of primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC)","volume":"17","author":"Mattner","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jceh.2021.08.017_bib24","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1111\/jcmm.14951","article-title":"Modulation of bile acid profile by gut microbiota in chronic hepatitis B","volume":"24","author":"Wang","year":"2020","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.jceh.2021.08.017_bib25","doi-asserted-by":"crossref","first-page":"G929","DOI":"10.1152\/ajpgi.00315.2013","article-title":"Colonic inflammation and secondary bile acids in alcoholic cirrhosis","volume":"306","author":"Kakiyama","year":"2014","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jceh.2021.08.017_bib26","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1038\/s41467-020-18754-5","article-title":"Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD","volume":"11","author":"Lee","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jceh.2021.08.017_bib27","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/gutjnl-2018-317836","article-title":"Alterations of gut microbiome in autoimmune hepatitis","volume":"69","author":"Wei","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2021.08.017_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.00342","article-title":"Fecal microbiomes distinguish patients with autoimmune hepatitis from healthy individuals","volume":"10","author":"Lou","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jceh.2021.08.017_bib29","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jhep.2017.04.026","article-title":"Biliary bile acids in hepatobiliary injury - what is the link?","volume":"67","author":"Fickert","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib30","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3748\/wjg.15.1677","article-title":"Bile-acid-induced cell injury and protection","volume":"15","author":"Perez","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2021.08.017_bib31","doi-asserted-by":"crossref","DOI":"10.21037\/atm-20-5110","article-title":"The role of bile acids in cholestatic liver injury","volume":"9","author":"Cai","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jceh.2021.08.017_bib32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.taap.2015.01.015","article-title":"Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis","volume":"283","author":"Woolbright","year":"2015","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.jceh.2021.08.017_bib33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ajpath.2010.11.026","article-title":"Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis","volume":"178","author":"Allen","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jceh.2021.08.017_bib34","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1111\/apt.14678","article-title":"Review article: therapeutic bile acids and the risks for hepatotoxicity","volume":"47","author":"Ashby","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2021.08.017_bib35","doi-asserted-by":"crossref","first-page":"G1109","DOI":"10.1152\/ajpgi.1997.272.5.G1109","article-title":"Bile salt-induced apoptosis of hepatocytes involves activation of protein kinase C","volume":"272","author":"Jones","year":"1997","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jceh.2021.08.017_bib36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3904\/kjim.1986.1.1.37","article-title":"Profiles of serum bile acids in liver diseases","volume":"1","author":"Kim","year":"1986","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jceh.2021.08.017_bib37","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0022-2143(03)00040-4","article-title":"Accurate enzymatic measurement of fecal bile acids in patients with malabsorption","volume":"141","author":"Porter","year":"2003","journal-title":"J\u00a0Lab Clin Med"},{"key":"10.1016\/j.jceh.2021.08.017_bib38","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4254\/wjh.v13.i4.433","article-title":"Bile acid indices as biomarkers for liver diseases I: diagnostic markers","volume":"13","author":"Alamoudi","year":"2021","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib39","first-page":"4058","article-title":"Role of bile acids in the diagnosis and progression of liver cirrhosis: a prospective observational study","volume":"18","author":"Liu","year":"2019","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jceh.2021.08.017_bib40","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/gut.14.11.895","article-title":"Cholic acid synthesis as an index of the severity of liver disease in man","volume":"14","author":"McCormick","year":"1973","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2021.08.017_bib41","doi-asserted-by":"crossref","first-page":"154457","DOI":"10.1016\/j.metabol.2020.154457","article-title":"Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression","volume":"116","author":"Nimer","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.jceh.2021.08.017_bib42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/gut.12.2.145","article-title":"Serum bile acids in liver disease","volume":"12","author":"Neale","year":"1971","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2021.08.017_bib43","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1021\/acs.jproteome.0c00852","article-title":"Bile acid profiles are distinct among patients with different etiologies of chronic liver disease","volume":"20","author":"Sang","year":"2021","journal-title":"J\u00a0Proteome Res"},{"key":"10.1016\/j.jceh.2021.08.017_bib44","article-title":"Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis B virus infection","volume":"99","author":"Yan","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jceh.2021.08.017_bib45","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1021\/acs.jproteome.5b00217","article-title":"Serum bile acids are associated with pathological progression of hepatitis B-induced cirrhosis","volume":"15","author":"Wang","year":"2016","journal-title":"J\u00a0Proteome Res"},{"key":"10.1016\/j.jceh.2021.08.017_bib46","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2893.2012.01628.x","article-title":"Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C","volume":"20","author":"Shlomai","year":"2013","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jceh.2021.08.017_bib47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12016-019-08731-2","article-title":"Comprehensive analysis of serum and fecal bile acid profiles and interaction with gut microbiota in primary biliary cholangitis","volume":"58","author":"Chen","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jceh.2021.08.017_bib48","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hep.31652","article-title":"Bile acid profiles in primary sclerosing cholangitis and their ability to predict hepatic decompensation","volume":"74","author":"Mousa","year":"2021","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jceh.2021.08.017_bib49","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1039\/C6MB00092D","article-title":"Metabolism of glycerophospholipid, bile acid and retinol is correlated with the early outcomes of autoimmune hepatitis","volume":"12","author":"Zhou","year":"2016","journal-title":"Mol Biosyst"},{"key":"10.1016\/j.jceh.2021.08.017_bib50","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/liv.13201","article-title":"Serum bile acids as marker for acute decompensation and acute-on-chronic liver failure in patients with non-cholestatic cirrhosis","volume":"37","author":"Horvatits","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2021.08.017_bib51","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1471-230X-8-47","article-title":"Bile composition in Alagille syndrome and PFIC patients having partial external biliary diversion","volume":"8","author":"Emerick","year":"2008","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jceh.2021.08.017_bib52","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2010.01.034","article-title":"Differences in presentation and progression between severe FIC1 and BSEP deficiencies","volume":"53","author":"Pawlikowska","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib53","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jpeds.2017.12.058","article-title":"Clinical, pathologic, and genetic features of neonatal Dubin-Johnson syndrome: a multicenter study in Japan","volume":"196","author":"Togawa","year":"2018","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jceh.2021.08.017_bib54","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jpedsurg.2011.08.010","article-title":"Normalization of serum bile acids after partial external biliary diversion indicates an excellent long-term outcome in children with progressive familial intrahepatic cholestasis","volume":"47","author":"Schukfeh","year":"2012","journal-title":"J\u00a0Pediatr Surg"},{"key":"10.1016\/j.jceh.2021.08.017_bib55","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MPG.0000000000001734","article-title":"Bile acid synthesis disorders in Arabs: a 10-year screening study","volume":"65","author":"Al-Hussaini","year":"2017","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jceh.2021.08.017_bib56","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MPG.0000000000002037","article-title":"Total bile acid concentration in duodenal fluid is a useful preoperative screening marker to rule out biliary atresia","volume":"67","author":"Fukuoka","year":"2018","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jceh.2021.08.017_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajg.2021.04.001","article-title":"Evaluation of the role of bile acids and serotonin as markers of pruritus in children with chronic cholestatic liver disease","author":"Koofy","year":"2021","journal-title":"Arab J Gastroenterol"},{"key":"10.1016\/j.jceh.2021.08.017_bib58","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jss.2018.03.021","article-title":"Liquid chromatography\u2013mass spectroscopy in the diagnosis of biliary atresia in children with hyperbilirubinemia","volume":"228","author":"Golden","year":"2018","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.jceh.2021.08.017_bib59","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib60","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1572-0241.2001.03777.x","article-title":"High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis","volume":"96","author":"Harnois","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jceh.2021.08.017_bib61","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/hep.1840140516","article-title":"Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study","volume":"14","author":"O'Brien","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.08.017_bib62","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S1590-8658(03)00076-8","article-title":"Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey","volume":"35","author":"Okolicsanyi","year":"2003","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jceh.2021.08.017_bib63","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.29882","article-title":"Design and endpoints for clinical trials in primary sclerosing cholangitis","volume":"68","author":"Ponsioen","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.08.017_bib64","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.dld.2010.12.008","article-title":"Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis","volume":"43","author":"Stanich","year":"2011","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jceh.2021.08.017_bib65","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2012.10.013","article-title":"Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis","volume":"58","author":"Al Mamari","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib66","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2020.07.032","article-title":"Inter- and intra-individual variation, and limited prognostic utility, of serum alkaline phosphatase in a trial of patients with primary sclerosing cholangitis","volume":"19","author":"Trivedi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib67","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1365-2036.2011.04822.x","article-title":"Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis","volume":"34","author":"Triantos","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2021.08.017_bib68","article-title":"Bile acids for primary sclerosing cholangitis","volume":"1","author":"Poropat","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jceh.2021.08.017_bib69","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.27074","article-title":"Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis","volume":"60","author":"Wunsch","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.08.017_bib70","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ajg.2015.112","article-title":"ACG clinical guideline: primary sclerosing cholangitis","volume":"110","author":"Lindor","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jceh.2021.08.017_bib71","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.08.017_bib72","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/hep.510250303","article-title":"Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis","volume":"25","author":"Jacquemin","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.08.017_bib73","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1055\/s-2008-1046459","article-title":"[Long-term ursodeoxycholic acid treatment of cholestatic liver diseases in childhood--clinical and biochemical effects]","volume":"208","author":"Kardorff","year":"1996","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.jceh.2021.08.017_bib74","first-page":"573","article-title":"Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid","volume":"24","author":"Balistreri","year":"1997","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jceh.2021.08.017_bib75","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1053\/gast.1996.v111.pm8780577","article-title":"Ursodeoxycholic acid for treatment of cholestasis in children on long- term total parenteral nutrition: a pilot study","volume":"111","author":"Spagnuolo","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2021.08.017_bib76","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S0140-6736(87)91208-6","article-title":"Treatment with ursodeoxycholic acid renders children with biliary atresia suitable for liver transplantation","volume":"2","author":"Ullrich","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2021.08.017_bib77","first-page":"49","article-title":"Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease","volume":"26","author":"Narkewicz","year":"1998","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jceh.2021.08.017_bib78","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/ncpgasthep1179","article-title":"Mechanisms of Disease: inborn errors of bile acid synthesis","volume":"5","author":"Sundaram","year":"2008","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib79","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6\u03b1-Ethyl-Chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jceh.2021.08.017_bib80","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2021.08.017_bib81","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2021.08.017_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.30940","article-title":"Oral Abstracts (Abstracts 1\u2013288)","volume":"70","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.08.017_bib83","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2021.08.017_bib84","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12664-020-01021-2","article-title":"Treatment of non-alcoholic fatty liver disease - current perspectives","volume":"39","author":"Elhence","year":"2020","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.jceh.2021.08.017_bib85","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2021.08.017_bib86","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2147\/TCRM.S113052","article-title":"New developments in the treatment of primary biliary cholangitis - role of obeticholic acid","volume":"13","author":"Jhaveri","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jceh.2021.08.017_bib87","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jceh.2021.08.017_bib88","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.08.017_bib89","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/cpdd.762","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel non\u2013bile acid FXR agonist tropifexor (LJN452) in healthy volunteers","volume":"9","author":"Badman","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jceh.2021.08.017_bib90","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1021\/acs.jmedchem.9b01621","article-title":"Nidufexor (LMB763), a novel FXR modulator for the treatment of nonalcoholic steatohepatitis","volume":"63","author":"Chianelli","year":"2020","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jceh.2021.08.017_bib91","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2021.08.017_bib92","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2021.08.017_bib93","doi-asserted-by":"crossref","first-page":"100255","DOI":"10.1016\/j.jhepr.2021.100255","article-title":"Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases","volume":"3","author":"Sanyal","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jceh.2021.08.017_bib94","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib95","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1074\/jbc.M115.699504","article-title":"Activation of transmembrane bile acid receptor TGR5 modulates pancreatic islet \u03b1 cells to promote glucose homeostasis","volume":"291","author":"Kumar","year":"2016","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jceh.2021.08.017_bib96","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bbrc.2005.01.139","article-title":"Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1","volume":"329","author":"Katsuma","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jceh.2021.08.017_bib97","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/JOE-17-0557","article-title":"INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function","volume":"238","author":"Comeglio","year":"2018","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.jceh.2021.08.017_bib98","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/hep.24047","article-title":"Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells","volume":"53","author":"He","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.08.017_bib99","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1097\/MCG.0000000000000591","article-title":"Combination therapy of all-trans retinoic acid with ursodeoxycholic acid in patients with primary sclerosing cholangitis: a human pilot study","volume":"51","author":"Assis","year":"2017","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.jceh.2021.08.017_bib100","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41401-018-0195-3","article-title":"A\u00a0novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters","volume":"40","author":"Ge","year":"2019","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.jceh.2021.08.017_bib101","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3748\/wjg.v27.i10.959","article-title":"Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"27","author":"Nadinskaia","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2021.08.017_bib102","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00508-020-01735-5","article-title":"Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease","volume":"133","author":"Traussnigg","year":"2021","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.jceh.2021.08.017_bib103","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jhep.2020.03.024","article-title":"Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study","volume":"73","author":"Newsome","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib104","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2021.08.017_bib105","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40360-018-0200-y","article-title":"A\u00a0randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis","volume":"19","author":"Palmer","year":"2018","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.jceh.2021.08.017_bib106","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.30590","article-title":"NGM282 improves liver fibrosis and histology in 12 Weeks in patients with nonalcoholic steatohepatitis","volume":"71","author":"Harrison","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.08.017_bib107","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2019.10.006","article-title":"Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis","volume":"72","author":"Siddiqui","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib108","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.jhep.2014.12.034","article-title":"Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity","volume":"62","author":"Mueller","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib109","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2021.08.017_bib110","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jhep.2010.08.030","article-title":"A\u00a0randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis","volume":"54","author":"Ratziu","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib111","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/hep.23727","article-title":"High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Leuschner","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.08.017_bib112","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.20092","article-title":"Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial","volume":"39","author":"Lindor","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.08.017_bib113","first-page":"1464","article-title":"Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study","volume":"23","author":"Laurin","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.08.017_bib114","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jhep.2020.07.028","article-title":"Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis","volume":"74","author":"Kj\u00e6rgaard","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib115","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A\u00a0randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib116","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study","volume":"389","author":"Hegade","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2021.08.017_bib117","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib118","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib119","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cgh.2019.09.050","article-title":"Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis","volume":"18","author":"Bowlus","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib120","article-title":"Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis","volume":"3","author":"Harms","year":"2021","journal-title":"JHEPReport"},{"key":"10.1016\/j.jceh.2021.08.017_bib121","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jhep.2020.03.043","article-title":"Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis","volume":"73","author":"Corpechot","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib122","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jhep.2012.02.014","article-title":"Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health","volume":"57","author":"Dilger","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib123","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2007.12.023","article-title":"High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective","volume":"48","author":"Cullen","year":"2008","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib124","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study","volume":"129","author":"Olsson","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2021.08.017_bib125","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S0168-8278(99)80136-6","article-title":"Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial","volume":"30","author":"Angulo","year":"1999","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib126","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199703063361003","article-title":"Ursodiol for primary sclerosing cholangitis","volume":"336","author":"Lindor","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2021.08.017_bib127","first-page":"1472","article-title":"Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period","volume":"43","author":"De Maria","year":"1996","journal-title":"Hepato-Gastroenterology"},{"key":"10.1016\/j.jceh.2021.08.017_bib128","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0168-8278(96)80293-5","article-title":"Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response","volume":"25","author":"van de Meeberg","year":"1996","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.017_bib129","doi-asserted-by":"crossref","first-page":"101751","DOI":"10.1016\/j.clinre.2021.101751","article-title":"Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: phase 2 study","volume":"45","author":"Baumann","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jceh.2021.08.017_bib130","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31787","article-title":"Impact of genotype, serum bile acids, and surgical biliary diversion on native liver survival in FIC1 deficiency","author":"van Wessel","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.08.017_bib131","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jpeds.2019.01.039","article-title":"Ursodeoxycholic acid therapy in pediatric primary sclerosing cholangitis: predictors of gamma glutamyltransferase normalization and favorable clinical course","volume":"209","author":"Deneau","year":"2019","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jceh.2021.08.017_bib132","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/hep4.1421","article-title":"A\u00a0prospective trial of withdrawal and reinstitution of ursodeoxycholic acid in pediatric primary sclerosing cholangitis","volume":"3","author":"Black","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jceh.2021.08.017_bib133","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/hep4.1244","article-title":"Placebo-controlled randomized trial of an intestinal bile salt transport inhibitor for pruritus in Alagille syndrome","volume":"2","author":"Shneider","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jceh.2021.08.017_bib134","doi-asserted-by":"crossref","first-page":"91","DOI":"10.24953\/turkjpediatr.1999.3203","article-title":"Ursodeoxycholic acid therapy in children with cholestatic liver disease","volume":"41","author":"Dinler","year":"1999","journal-title":"Turk J Pediatr"},{"key":"10.1016\/j.jceh.2021.08.017_bib135","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1046\/j.1442-200x.1999.01143.x","article-title":"Ursodeoxycholic acid treatment in children with Byler disease","volume":"41","author":"Dinler","year":"1999","journal-title":"Pediatr Int"},{"key":"10.1016\/j.jceh.2021.08.017_bib136","unstructured":"Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis - PubMed. Accessed August 9, 2021. https:\/\/pubmed.ncbi.nlm.nih.gov\/29654817\/."},{"key":"10.1016\/j.jceh.2021.08.017_bib137","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.3390\/cancers13112648","article-title":"Association between pre-diagnostic serum bile acids and hepatocellular carcinoma: the Singapore Chinese health study","volume":"13","author":"Thomas","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jceh.2021.08.017_bib138","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1002\/ijc.33051","article-title":"Prediagnostic concentrations of circulating bile acids and hepatocellular carcinoma risk: REVEAL-HBV and HCV studies","volume":"147","author":"Petrick","year":"2020","journal-title":"Int J Cancer"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S097368832100222X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S097368832100222X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:07:01Z","timestamp":1760854021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S097368832100222X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":138,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S097368832100222X"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2021.08.017","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Current Understanding of Bile Acids in Chronic Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2021.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}